ACE-083 is a locally acting muscle therapeutic based on follistatin that binds myostatin and other muscle regulators. ACE-083 increased muscle mass and force in mouse models and muscle mass in healthy volunteers. Facioscapulohumeral dystrophy (FSHD) is characterized by weakness in various muscles, including those of the upper arm and lower leg. We are conducting a 2-part trial of ACE-083 in patients with FSHD; Part 1 is open-label, ascending dose and Part 2 is double-blind, placebo-controlled. Here we report results from Part 1.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...